Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk

Morgana Mongraw-Chaffin, Meredith C. Foster, Cheryl A.M. Anderson, Gregory L. Burke, Nowreen Haq, Rita R. Kalyani, Pamela Ouyang, Christopher Sibley, Russell Tracy, Mark Woodward, Dhananjay Vaidya

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Debate over the cardiometabolic risk associated with metabolically healthy obesity (MHO) continues. Many studies have investigated this relationship by examining MHO at baseline with longitudinal follow-up, with inconsistent results. Objectives: The authors hypothesized that MHO at baseline is transient and that transition to metabolic syndrome (MetS) and duration of MetS explains heterogeneity in incident cardiovascular disease (CVD) and all-cause mortality. Methods: Among 6,809 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) the authors used Cox proportional hazards and logistic regression models to investigate the joint association of obesity (≥30 kg/m2) and MetS (International Diabetes Federation consensus definition) with CVD and mortality across a median of 12.2 years. We tested for interaction and conducted sensitivity analyses for a number of conditions. Results: Compared with metabolically healthy normal weight, baseline MHO was not significantly associated with incident CVD; however, almost one-half of those participants developed MetS during follow-up (unstable MHO). Those who had unstable MHO had increased odds of CVD (odds ratio [OR]: 1.60; 95% confidence interval [CI]: 1.14 to 2.25), compared with those with stable MHO or healthy normal weight. Dose response for duration of MetS was significantly and linearly associated with CVD (1 visit with MetS OR: 1.62; 95% CI: 1.27 to 2.07; 2 visits, OR: 1.92; 95% CI: 1.48 to 2.49; 3+ visits, OR: 2.33; 95% CI: 1.89 to 2.87; p value for trend <0.001) and MetS mediated approximately 62% (44% to 100%) of the relationship between obesity at any point during follow-up and CVD. Conclusions: Metabolically healthy obesity is not a stable or reliable indicator of future risk for CVD. Weight loss and lifestyle management for CVD risk factors should be recommended to all individuals with obesity.

Original languageEnglish (US)
Pages (from-to)1857-1865
Number of pages9
JournalJournal of the American College of Cardiology
Volume71
Issue number17
DOIs
StatePublished - May 1 2018
Externally publishedYes

Fingerprint

Metabolic Syndrome X
Cardiovascular Diseases
Odds Ratio
Confidence Intervals
Obesity
Logistic Models
Weights and Measures
Mortality
Metabolically Benign Obesity
Life Style
Weight Loss
Atherosclerosis

Keywords

  • cardiovascular disease
  • epidemiology
  • metabolic syndrome
  • metabolically healthy obesity
  • mortality
  • obesity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Mongraw-Chaffin, M., Foster, M. C., Anderson, C. A. M., Burke, G. L., Haq, N., Kalyani, R. R., ... Vaidya, D. (2018). Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. Journal of the American College of Cardiology, 71(17), 1857-1865. https://doi.org/10.1016/j.jacc.2018.02.055

Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. / Mongraw-Chaffin, Morgana; Foster, Meredith C.; Anderson, Cheryl A.M.; Burke, Gregory L.; Haq, Nowreen; Kalyani, Rita R.; Ouyang, Pamela; Sibley, Christopher; Tracy, Russell; Woodward, Mark; Vaidya, Dhananjay.

In: Journal of the American College of Cardiology, Vol. 71, No. 17, 01.05.2018, p. 1857-1865.

Research output: Contribution to journalArticle

Mongraw-Chaffin, M, Foster, MC, Anderson, CAM, Burke, GL, Haq, N, Kalyani, RR, Ouyang, P, Sibley, C, Tracy, R, Woodward, M & Vaidya, D 2018, 'Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk', Journal of the American College of Cardiology, vol. 71, no. 17, pp. 1857-1865. https://doi.org/10.1016/j.jacc.2018.02.055
Mongraw-Chaffin, Morgana ; Foster, Meredith C. ; Anderson, Cheryl A.M. ; Burke, Gregory L. ; Haq, Nowreen ; Kalyani, Rita R. ; Ouyang, Pamela ; Sibley, Christopher ; Tracy, Russell ; Woodward, Mark ; Vaidya, Dhananjay. / Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk. In: Journal of the American College of Cardiology. 2018 ; Vol. 71, No. 17. pp. 1857-1865.
@article{17aef865c0e4481e89eaedc9b9f5b957,
title = "Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk",
abstract = "Background: Debate over the cardiometabolic risk associated with metabolically healthy obesity (MHO) continues. Many studies have investigated this relationship by examining MHO at baseline with longitudinal follow-up, with inconsistent results. Objectives: The authors hypothesized that MHO at baseline is transient and that transition to metabolic syndrome (MetS) and duration of MetS explains heterogeneity in incident cardiovascular disease (CVD) and all-cause mortality. Methods: Among 6,809 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) the authors used Cox proportional hazards and logistic regression models to investigate the joint association of obesity (≥30 kg/m2) and MetS (International Diabetes Federation consensus definition) with CVD and mortality across a median of 12.2 years. We tested for interaction and conducted sensitivity analyses for a number of conditions. Results: Compared with metabolically healthy normal weight, baseline MHO was not significantly associated with incident CVD; however, almost one-half of those participants developed MetS during follow-up (unstable MHO). Those who had unstable MHO had increased odds of CVD (odds ratio [OR]: 1.60; 95{\%} confidence interval [CI]: 1.14 to 2.25), compared with those with stable MHO or healthy normal weight. Dose response for duration of MetS was significantly and linearly associated with CVD (1 visit with MetS OR: 1.62; 95{\%} CI: 1.27 to 2.07; 2 visits, OR: 1.92; 95{\%} CI: 1.48 to 2.49; 3+ visits, OR: 2.33; 95{\%} CI: 1.89 to 2.87; p value for trend <0.001) and MetS mediated approximately 62{\%} (44{\%} to 100{\%}) of the relationship between obesity at any point during follow-up and CVD. Conclusions: Metabolically healthy obesity is not a stable or reliable indicator of future risk for CVD. Weight loss and lifestyle management for CVD risk factors should be recommended to all individuals with obesity.",
keywords = "cardiovascular disease, epidemiology, metabolic syndrome, metabolically healthy obesity, mortality, obesity",
author = "Morgana Mongraw-Chaffin and Foster, {Meredith C.} and Anderson, {Cheryl A.M.} and Burke, {Gregory L.} and Nowreen Haq and Kalyani, {Rita R.} and Pamela Ouyang and Christopher Sibley and Russell Tracy and Mark Woodward and Dhananjay Vaidya",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.jacc.2018.02.055",
language = "English (US)",
volume = "71",
pages = "1857--1865",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "17",

}

TY - JOUR

T1 - Metabolically Healthy Obesity, Transition to Metabolic Syndrome, and Cardiovascular Risk

AU - Mongraw-Chaffin, Morgana

AU - Foster, Meredith C.

AU - Anderson, Cheryl A.M.

AU - Burke, Gregory L.

AU - Haq, Nowreen

AU - Kalyani, Rita R.

AU - Ouyang, Pamela

AU - Sibley, Christopher

AU - Tracy, Russell

AU - Woodward, Mark

AU - Vaidya, Dhananjay

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background: Debate over the cardiometabolic risk associated with metabolically healthy obesity (MHO) continues. Many studies have investigated this relationship by examining MHO at baseline with longitudinal follow-up, with inconsistent results. Objectives: The authors hypothesized that MHO at baseline is transient and that transition to metabolic syndrome (MetS) and duration of MetS explains heterogeneity in incident cardiovascular disease (CVD) and all-cause mortality. Methods: Among 6,809 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) the authors used Cox proportional hazards and logistic regression models to investigate the joint association of obesity (≥30 kg/m2) and MetS (International Diabetes Federation consensus definition) with CVD and mortality across a median of 12.2 years. We tested for interaction and conducted sensitivity analyses for a number of conditions. Results: Compared with metabolically healthy normal weight, baseline MHO was not significantly associated with incident CVD; however, almost one-half of those participants developed MetS during follow-up (unstable MHO). Those who had unstable MHO had increased odds of CVD (odds ratio [OR]: 1.60; 95% confidence interval [CI]: 1.14 to 2.25), compared with those with stable MHO or healthy normal weight. Dose response for duration of MetS was significantly and linearly associated with CVD (1 visit with MetS OR: 1.62; 95% CI: 1.27 to 2.07; 2 visits, OR: 1.92; 95% CI: 1.48 to 2.49; 3+ visits, OR: 2.33; 95% CI: 1.89 to 2.87; p value for trend <0.001) and MetS mediated approximately 62% (44% to 100%) of the relationship between obesity at any point during follow-up and CVD. Conclusions: Metabolically healthy obesity is not a stable or reliable indicator of future risk for CVD. Weight loss and lifestyle management for CVD risk factors should be recommended to all individuals with obesity.

AB - Background: Debate over the cardiometabolic risk associated with metabolically healthy obesity (MHO) continues. Many studies have investigated this relationship by examining MHO at baseline with longitudinal follow-up, with inconsistent results. Objectives: The authors hypothesized that MHO at baseline is transient and that transition to metabolic syndrome (MetS) and duration of MetS explains heterogeneity in incident cardiovascular disease (CVD) and all-cause mortality. Methods: Among 6,809 participants of the MESA (Multi-Ethnic Study of Atherosclerosis) the authors used Cox proportional hazards and logistic regression models to investigate the joint association of obesity (≥30 kg/m2) and MetS (International Diabetes Federation consensus definition) with CVD and mortality across a median of 12.2 years. We tested for interaction and conducted sensitivity analyses for a number of conditions. Results: Compared with metabolically healthy normal weight, baseline MHO was not significantly associated with incident CVD; however, almost one-half of those participants developed MetS during follow-up (unstable MHO). Those who had unstable MHO had increased odds of CVD (odds ratio [OR]: 1.60; 95% confidence interval [CI]: 1.14 to 2.25), compared with those with stable MHO or healthy normal weight. Dose response for duration of MetS was significantly and linearly associated with CVD (1 visit with MetS OR: 1.62; 95% CI: 1.27 to 2.07; 2 visits, OR: 1.92; 95% CI: 1.48 to 2.49; 3+ visits, OR: 2.33; 95% CI: 1.89 to 2.87; p value for trend <0.001) and MetS mediated approximately 62% (44% to 100%) of the relationship between obesity at any point during follow-up and CVD. Conclusions: Metabolically healthy obesity is not a stable or reliable indicator of future risk for CVD. Weight loss and lifestyle management for CVD risk factors should be recommended to all individuals with obesity.

KW - cardiovascular disease

KW - epidemiology

KW - metabolic syndrome

KW - metabolically healthy obesity

KW - mortality

KW - obesity

UR - http://www.scopus.com/inward/record.url?scp=85045479716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045479716&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2018.02.055

DO - 10.1016/j.jacc.2018.02.055

M3 - Article

VL - 71

SP - 1857

EP - 1865

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 17

ER -